COMMUNIQUÉS West-GlobeNewswire

Oncology Venture provides news on its clinical development projects dovitinib, 2X‑121 and LiPlaCis

30/04/2019 - 10:25

Press release Hørsholm, Denmark and Cambridge, MA, US, April 30, 2019 – Oncology Venture A/S today provides news on DRP ® based analyses of biopsies from clinical trials with dovitinib. In addition to renal, endometrial [...]

Saniona publishes the Annual Report for 2018

30/04/2019 - 10:15

PRESS RELEASE April 30, 2019 Saniona (OMX: SANION), a biotech company focused on the treatment of eating disorders and diseases of the central nervous system, announced today that the English version of the Annual [...]

BrainStorm’s Cellular Technology Platform Expanded to Include Exosomes for Neurodegenerative Diseases

30/04/2019 - 10:00

NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc. , ( NASDAQ: BCLI ), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced that it has expanded [...]

Solo Growth Corp™ Announces Fourth Quarter and Year End 2018 Results and Recent Operational Highlights

30/04/2019 - 03:35

CALGARY, Alberta, April 29, 2019 (GLOBE NEWSWIRE) -- Solo Growth Corp.™ (the “ Company ” or “ Solo Growth ”) (TSXV: SOLO) (WKN:A2PBMC), a cannabis retailer operating as YSS™ with the vision to become a premier retailer [...]

Helix BioPharma Corp. Closes Second Tranche of Private Placement

30/04/2019 - 00:54

RICHMOND HILL, Ontario, April 29, 2019 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment [...]

Eye Consultants of Northern Virginia, PC Pleased to Welcome Leah Fuchs, MD

29/04/2019 - 23:13

SPRINGFIELD, Va., April 29, 2019 (GLOBE NEWSWIRE) -- Eye Consultants of Northern Virginia, PC is pleased to welcome Leah Fuchs, MD to their practice. Dr. Fuchs is a board-certified ophthalmologist who specializes in [...]

XORTX Provides Overview and Announces $5 Million Financing to Advance Clinical Trials

29/04/2019 - 23:09

Pivotal Registration Clinical Study with XRx-008 and Phase 2b Clinical Study withTMX-049 Planned in 2020 CALGARY, Alberta, April 29, 2019 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (CSE: [...]

TCR2 Therapeutics Announces First Quarter 2019 Earnings Conference Call and Webcast

29/04/2019 - 22:30

Earnings to be released after market close on Monday, May 13, 2019 CAMBRIDGE, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- TCR 2 Therapeutics Inc. (TCR 2 ) (Nasdaq: TCRR), a clinical-stage immunotherapy company developing [...]

Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results

29/04/2019 - 22:30

DUBLIN, Ireland, April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live [...]

Repligen Corporation Announces Proposed Public Offering of Shares of Common Stock

29/04/2019 - 22:19

WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, [...]

Novan Secures Up to $35 Million in Non-Dilutive Funding

29/04/2019 - 22:15

$25 million provided immediately in exchange for participation in future potential cash flows Additional $10 million available upon achieving success in molluscum Phase 3 top line results Pipeline Priority: initiation [...]

Precision BioSciences Reports First Quarter 2019 Financial Results

29/04/2019 - 22:15

DURHAM, N.C., April 29, 2019 (GLOBE NEWSWIRE) -- Precision BioSciences, a genome editing company dedicated to improving life (Nasdaq: DTIL) (“Precision”) through the application of its proprietary ARCUS genome editing [...]

Alimera Sciences Announces First Quarter 2019 Financial Results and Provides Corporate Overview

29/04/2019 - 22:15

First Quarter and Recent Company Highlights: Global revenue up 34% versus Q1 2018 Regulatory approval obtained for ILUVIEN ® in 17 EU countries for the treatment of Non-Infectious Posterior Uveitis Samer Kaba, M.D. [...]

Otonomy to Report First Quarter 2019 Financial Results and Provide Corporate Update

29/04/2019 - 22:05

Webcast and Conference Call to be Held at 4:30 p.m. EDT on May 6, 2019 SAN DIEGO, April 29, 2019 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative [...]

Silk Road Medical to Report First Quarter 2019 Financial Results on May 8, 2019

29/04/2019 - 22:05

SUNNYVALE, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced it will report financial results [...]

SI-BONE to Present at the Bank of America Merrill Lynch 2019 Health Care Conference

29/04/2019 - 22:05

SANTA CLARA, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that management [...]

Sunesis Pharmaceuticals Announces Refinancing of Existing Loan with $5.5 Million Loan from Silicon Valley Bank

29/04/2019 - 22:05

SOUTH SAN FRANCISCO, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today announced that it has entered into a $5.5 million loan agreement with Silicon Valley Bank . The new [...]

Precision Optics Corporation, Inc. Announces Receipt of $2.2 Million Order For Custom Designed Cardiovascular Endoscope

29/04/2019 - 22:05

GARDNER, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (OTCQB: PEYE) today announced that it has received a follow-on order totaling $2,216,000 from CardioFocus, Inc. for the manufacture [...]

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2019 Financial Results

29/04/2019 - 22:01

-Enrollment ongoing in Phase 1/2 clinical trials of CTX001™ for patients with severe hemoglobinopathies- -IND and CTA approved for CTX110™, wholly-owned allogeneic CAR-T cell therapy targeting CD19+ malignancies- -On [...]